Lenz Therapeutics, INC Form 4 insider transactions

RA Capital Management reports a stock option grant for Dr. Zachary Scheiner, a director at LENZ Therapeutics, Inc.

Director Jeffrey P. George was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of standard compensation.

Director Kimberlee C. Drapkin was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of standard compensation.

Director James W. McCollum was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's director compensation policy.

Director Shelley B. Thunen was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's compensation policy.

Director Frederic Guerard was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's director compensation policy.

Director Zachary Scheiner was granted 22,100 stock options in LENZ Therapeutics, which he holds for the benefit of RA Capital Management.

Director Jeffrey P. George purchased 5,592 LENZ shares on March 27, 2026 at a weighted average price of $8.9217 in open-market trades.

LENZ Therapeutics CEO Evert B. Schimmelpennink purchased 28,089 shares at a weighted average $8.9505, lifting his direct holdings to 77,289 shares.

LENZ Therapeutics CFO Daniel R. Chevallard purchased 7,500 common shares on March 27, 2026 at $8.57, increasing his direct holdings to 12,886.

LENZ Therapeutics' Chief Commercial Officer, Shawn Olsson, was granted 84,200 stock options and 14,000 restricted stock units, vesting over several years.

LENZ Therapeutics' Chief Medical Officer, Marc Odrich, was granted 84,200 stock options and 14,000 restricted stock units, effective January 2, 2026.

LENZ Therapeutics' Chief Financial Officer, Daniel R. Chevallard, received grants of 84,200 stock options and 14,000 restricted stock units.

LENZ Therapeutics' President, CEO, and Secretary, Evert B. Schimmelpennink, was granted 358,100 stock options with an exercise price of $16, vesting over several years.

LENZ Therapeutics' Chief Commercial Officer, Shawn Olsson, exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.

LENZ Therapeutics Director James W. McCollum purchased 10,500 shares of common stock at a weighted average price of $22.7884.

LENZ Therapeutics' Chief Financial Officer, Daniel R. Chevallard, reported open market purchases of company common stock.

Versant Venture Capital VI, L.P. and affiliated entities reported multiple sales of LENZ Therapeutics, Inc. common stock on September 30, 2025, reducing their beneficial ownership.

Versant Venture Capital VI, L.P. and affiliated entities reported sales of LENZ Therapeutics, Inc. common stock totaling 135,304 shares on September 18, 2025, executed under a Rule 10b5-1 plan.

Versant Venture Capital entities, a 10% owner and director of LENZ Therapeutics, reported the sale of 188,094 common shares for approximately $7.4 million in late August 2025.

Versant Venture Capital entities, a 10% owner and director of LENZ Therapeutics, Inc., reported sales of common stock totaling 260,713 shares across two dates in August 2025 under a Rule 10b5-1 plan.

Versant Venture Capital entities, a 10% owner and director of LENZ Therapeutics, Inc., reported the sale of 191,376 shares of common stock for $34 per share.

Versant Venture Capital VI, L.P., along with affiliated entities, reported the sale of 200,000 shares of LENZ Therapeutics, Inc. common stock for approximately $6.09 million.

Versant Venture Capital entities, a 10% owner and director of LENZ Therapeutics, Inc., reported the sale of 334,801 shares of common stock in mid-June 2025.

Versant Venture Capital, a significant shareholder and director in LENZ Therapeutics, Inc., has sold 350,000 shares of common stock for $29 per share as part of a pre-arranged Rule 10b5-1 trading plan.

RA Capital Management and its affiliates have disclosed the grant of 13,500 stock options to director Zachary Scheiner, exercisable at $30 per share, under LENZ Therapeutics' Outside Director Compensation Policy.

Jeffrey P. George, a Director at LENZ Therapeutics, Inc., was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

LENZ Therapeutics, Inc. Director Kimberlee C. Drapkin was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

LENZ Therapeutics, Inc. Director Frederic Guerard was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

Shelley B. Thunen, a Director at LENZ Therapeutics, Inc., was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.